Ordenar

Buscar

01/06/2026 Safety and Efficacy of Epirubicin, Ifosfamide, and Nivolumab as First-Line Treatment for Patients with Undifferentiated Pleomorphic Sarcoma
Martin-Broto, J, Martinez-Trufero, J, Diaz-Beveridge, R, Gutierrez, A, Carrasco, I, Lopez-Jimenez, C, Sebio, A, González-Billalabeitia, E, Ramos, R, Romagosa, C, Merino, J, Fernandez-Jara, J, Hernandez-Vargas, L, Garmendia, MD, Cruz-Jurado, J, Valverde, C, Mondaza-Hernandez, JL, Carrera, MA, Ledesma, P, Hindi, N, Moura, DS. Safety and Efficacy of Epirubicin, Ifosfamide, and Nivolumab as First-Line Treatment for Patients with Undifferentiated Pleomorphic Sarcoma. CLINICAL CANCER RESEARCH. 2026; 32(11)DOI:10.1158/1078-0432.CCR-26-0032. PMID:41817407. IF:10.200(Q1/1D).
01/06/2026 PM534, a Novel Colchicine Site Tubulin Inhibitor with Broad-Spectrum and Resistance-Overcoming Antitumor Activity
Aviles, P, Ribeiro, ML, Guillén, MJ, Martinez-Diez, M, Muñoz-Alonso, MJ, Santamaria-Nuñez, G, Torralba, D, Alamo, P, Gallardo, A, Oliva, MA, Mangues, R, Diaz, JF, Cuevas, C. PM534, a Novel Colchicine Site Tubulin Inhibitor with Broad-Spectrum and Resistance-Overcoming Antitumor Activity. MOLECULAR CANCER THERAPEUTICS. 2026; 25(6)DOI:10.1158/1535-7163.MCT-25-0559. PMID:41481906. IF:5.500(Q1/2D).
01/06/2026 Monotherapy vs. combination therapy for Enterococcus faecalis bacteraemia: a target trial emulation
Bartoletti, M, Del Turco, ER, Bussini, L, Paul, M, Sabik, EF, Castagna, A, Ripa, M, Gomes, MZR, Di Bella, S, Malosso, M, Lopez, AB, Franceschini, E, Bandera, A, Barbieri, V, Oliva, A, Munoz, P, Mularoni, A, Seminari, E, Morelli, P, Tascini, C, Papadimitriou-Olivgeris, M, Coppola, N, Cristini, F, Russo, A, Bassetti, M, Travi, G, Contreras, JL, Varisco, B, Viale, P, Cento, V, Gaibani, P, Bavaro, DF, Giannella, M. Monotherapy vs. combination therapy for Enterococcus faecalis bacteraemia: a target trial emulation. CLINICAL MICROBIOLOGY AND INFECTION. 2026; 32(6)DOI:10.1016/j.cmi.2026.03.018. PMID:41850617. IF:8.500(Q1/1D).
01/06/2026 Quality indicators for clinical infectious diseases consultations?results from a hybrid Delphi-nominal group approach and scenario study
Hornuss, D, Mathé, P, Giesen, R, Escolà-Vergé, L, Isler, B, Bartoletti, M, Lamy, B, Wagner, D, Kern, WV, Rieg, S. Quality indicators for clinical infectious diseases consultations?results from a hybrid Delphi-nominal group approach and scenario study. CLINICAL MICROBIOLOGY AND INFECTION. 2026; 32(6)DOI:10.1016/j.cmi.2026.03.006. PMID:41831716. IF:8.500(Q1/1D).